Richardson PG, et al. - In patients suffering relapsed or refractory multiple myeloma despite the previous receipt of lenalidomide, researchers performed this randomized, open-label, phase 3 trial to evaluate the effectiveness and safety of the combination of pomalidomide, bortezomib, and dexamethasone. They randomly allocated (1:1) patients to bortezomib and dexamethasone with or without pomalidomide. They found significantly improved progression-free survival in relation to treatment with pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in these patients who previously received lenalidomide. They noted adverse events accorded with the individual profiles of pomalidomide, bortezomib, and dexamethasone. In such a patient populace, treatment with pomalidomide, bortezomib, and dexamethasone was supported in this study.